Sansure Biotech(SH:688289) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-10-22 00:53Core Viewpoint - The company plans to establish a venture capital partnership with Suzhou Weitili New Venture Capital Management Co., Ltd. to extend its industrial chain and strategic layout, with an investment of RMB 20 million, accounting for 19.80% of the total fund [1][3]. Group 1: Investment Details - The fund aims to raise a total of RMB 200 million, with an initial fundraising target of RMB 101 million, focusing on innovative companies in the healthcare sector, including medical devices, biomedicine, and health management [3][12]. - The company will contribute RMB 20 million as a limited partner, representing a 19.80% stake in the fund [1][3]. - The fund's management will be conducted by a professional investment management team, with a decision-making committee to enhance investment decision-making [7][11]. Group 2: Related Transactions - This investment constitutes a related party transaction but does not qualify as a major asset restructuring, thus not requiring shareholder approval [4][18]. - The company has not engaged in any significant related transactions with the same related party in the past 12 months, ensuring compliance with regulatory requirements [19]. Group 3: Impact on the Company - The partnership with Weitili New is expected to enhance the company's investment channels, improve risk management, and support strategic planning, ultimately strengthening its competitive position [18]. - The investment will not be included in the company's consolidated financial statements, and the investment risk is limited to the amount contributed [18].